|
3rd International Workshop on HIV Drug Resistance & Treatment Strategies23-26 June 1999, San Diego, California, USA |
|
Session 1: New antiretrovirals Abstracts 1 thru 19, Pages 3 to 14 |
|
| 1 | INHIBITORS OF HIV INTEGRASE: ANTIVIRAL ACTIVITY AND MECHANISM Antiviral Therapy 1999;4 (Suppl 1):3 DJ Hazuda The HIV-1 enzyme integrase represents a potential target for the development of selective antiretroviral agents. We have identified novel inhibitors of integrase that block integration and inhibit HIV-1 replication in cells. The isolation and characterization of resistant viral isolates has established integrase as the specific target of inhibition thus validating integrase as a viable target for chemotherapeutic intervention. |
| 2 | ANTI-HIV ACTIVITY AND CROSS-RESISTANCE PROFILE OF NOVEL 2'-FLUORO-2',3'-UNSATURATED D- AND L-NUCLEOSIDES (D4N) Antiviral Therapy 1999;4 (Suppl 1):3 RF Schinazi1, S Schlueter-Wirtz1, P Tharnish1, D Joiner1, T Barnett1, K Lee2, YS Choi2 and CK Chu2 We recently identified D-D4FC as a highly potent and selective inhibitor of HIV-1 and HIV-2 with a unique cross-resistance profile. However, certain d4N are unstable under acidic conditions. We reasoned that introducing a vinylic fluoride moiety into the D- and L-nucleosides should eliminate this potential problem. The strategy for the synthesis of more than 30 analogues was based on direct coupling of the sugar moiety with a variety of heterocycles to obtain our target compounds. |
| 3 | THE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR DAPD IS ACTIVE AGAINST RESISTANT HIV-1 ISOLATES FROM PATIENTS FAILING STANDARD NUCLEOSIDE THERAPY Antiviral Therapy 1999;4 (Suppl 1):4 K Borroto-Esoda, J Mewshaw, D Wakefield, B Hooper, J Jeffrey, P Furman and B McCreedy DAPD, (–)-β-D-2,6-diaminopurine dioxolane, is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against HIV-1 and hepatitis B virus. DAPD is deaminated in vivo by adenosine deaminase to give (–)- β-D-dioxolane guanine (DXG). Biochemical analysis of the 5' triphosphates of DAPD and DXG demonstrated that DXG 5'-triphosphate is a potent inhibitor of the HIV RT with a Ki of 0.019 µM. |
| 4 | COMBINATION ANTI-HIV AND RESISTANCE PROFILES FOR SJ-3366: A NEW NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR OF HIV-1 WITH ACTIVITY AGAINST HIV-2 Antiviral Therapy 1999;4 (Suppl 1):4 RW Buckheit Jr1, TL Stup1, V Fliakas-Boltz1, JM Russell1, J-W Lee2, S-H Lee2, J-W Oh2, H-S Kwon2, S-G Chung2 and E-H Cho2 We have identified and characterized a potent new non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1 that also is inhibitory against HIV-2. SJ-3366 inhibits HIV-1 replication at concentrations below 1 nM with a therapeutic index of greater than 4,000,000. SJ-3366 inhibited HIV-2 at a concentration of approximately 150 nM with a therapeutic index of nearly 20,000. |
| 5 | TIPRANAVIR IS ACTIVE AGAINST A LARGE SELECTION OF HIGHLY PROTEASE INHIBITOR-RESISTANT HIV-1 CLINICAL SAMPLES Antiviral Therapy 1999;4 (Suppl 1):5 B Larder1, S Bloor1, K Hertogs2, C Van Den Eynde2, W DeCian3, Y Wang4 and W Freimuth4 Treatment with HIV protease inhibitors (PIs) can lead to class cross-resistance, rendering all current PIs less effective. Since considerable numbers of patients failing HAART harbour PI-resistant virus, the development of new PIs active against these variants is an urgent priority. Unlike all available PIs, tipranavir is a new non-peptidic PI that binds in a flexible manner to the protease active site, making it potentially active against HIV resistant to all approved peptidic PIs. |
| 6 | KINETIC CHARACTERIZATION OF RS-344, AN HIV-1 PROTEASE INHIBITOR DESIGNED WITH A 'RESISTANT REPELLENT' CORE Antiviral Therapy 1999;4 (Suppl 1):5 L Suvorov, S Gulnik, E Gustchina, B Yu, R Randad, M Eissenstat and J Erickson Despite the current success in HIV treatment with protease inhibitors, the emergence of resistant virus strains limits effectiveness of such compounds. The acquisition of mutations in HIV protease, especially in the active site regions, resulted in a high degree of cross-resistance towards many different protease inhibitors, including all clinically approved drugs. Using structure-based approaches a novel flexible core was designed to target some of the active site mutants. Using a continuous fluorogenic assay, we measured the inhibition constants for one such inhibitor, RS-344, towards wild-type and seven different drug-resistant mutant enzymes. |
| 7 | ABT-378/RITONAVIR (ABT-378R) IN PROTEASE INHIBITOR-EXPERIENCED HIV-INFECTED PATIENTS: PRELIMINARY 24 WEEK RESULTS Antiviral Therapy 1999;4 (Suppl 1):6 C Benson2, S Brun1, Y Xu1, K Orth1, S Deeks3, H Kessler4, R Murphy5, D Wheeler6, C Hicks7, J Eron8, J Feinberg9, R Gulick10, P Sax11, R Stryker12, S Riddler13, M Thompson14, M King1, C Fields1, A Potthoff1, B Bernstein1, A Hsu1, R Bertz1, A Molla1, H Mo1, D Kempf1, E Sun1 and A Japour1 ABT-378/r is well tolerated and has antiretroviral activity among patients who experienced virological rebound following treatment with a single PI-based triple regimen. |
| 8 | ANALYSIS OF VIROLOGICAL RESPONSE TO ABT-378/RITONAVIR THERAPY IN PROTEASE INHIBITOR-EXPERIENCED PATIENTS WITH RESPECT TO BASELINE VIRAL PHENOTYPE AND GENOTYPE Antiviral Therapy 1999;4 (Suppl 1):7 D Kempf1, H Mo1, S Brun1, A Molla1, B Bernstein1, K Hertogs2, B Larder3, K Orth1, C Fields1, M King1, Y Xu1, A Japour1, E Sun1 and the M97-765 Study Team Because of high and sustained plasma levels, ABT-378/ritonavir regimens suppress VL in many PI-experienced patients for ≥24 weeks despite significant resistance to PIs and RTIs. However, virological response in this population is lower than in naive patients. The use of accompanying agents expected to have activity, in addition to ABT378/ritonavir, is likely to be necessary for a durable antiretroviral response. |
| 9 | HIV-1 RESISTANCE TO BINDING/FUSION INHIBITORS Antiviral Therapy 1999;4 (Suppl 1):7 JA Esté1 and E De Clercq2 The replicative cycle of HIV can be interrupted at several stages. The reverse transcriptase (RT) and protease are the enzymes currently targeted by approved antiretroviral agents. |
| 10 | Antiviral Therapy 1999;4 (Suppl 1):8 Abstract not available at this time. |
| 11 | Antiviral Therapy 1999;4 (Suppl 1):8 Abstract not available at this time. |
| 12 | Antiviral Therapy 1999;4 (Suppl 1):9 Abstract not available at this time. |
| 13 | Antiviral Therapy 1999;4 (Suppl 1):10 Abstract not available at this time. |
| 14 | Antiviral Therapy 1999;4 (Suppl 1):13 Abstract not available at this time. |
| 15 | Antiviral Therapy 1999;4 (Suppl 1):14 Abstract not available at this time. |
| 16 | Antiviral Therapy 1999;4 (Suppl 1):14 Abstract not available at this time. |
| 17 | Antiviral Therapy 1999;4 (Suppl 1):15 Abstract not available at this time. |
| 18 | Antiviral Therapy 1999;4 (Suppl 1):16 Abstract not available at this time. |
| 19 | Antiviral Therapy 1999;4 (Suppl 1):16 Abstract not available at this time. |
|
Session 2: Mechanisms of antiretroviral resistance Abstract 20 thru 57, Pages 15 to 38 |
|
| 20 | Antiviral Therapy 1999;4 (Suppl 1):17 Abstract not available at this time. |
| 21 | Antiviral Therapy 1999;4 (Suppl 1):18 Abstract not available at this time. |
| 22 | Antiviral Therapy 1999;4 (Suppl 1):18 Abstract not available at this time. |
| 23 | Antiviral Therapy 1999;4 (Suppl 1):19 Abstract not available at this time. |
| 24 | Antiviral Therapy 1999;4 (Suppl 1):20 Abstract not available at this time. |
| 25 | Antiviral Therapy 1999;4 (Suppl 1):20 Abstract not available at this time. |
| 26 | Antiviral Therapy 1999;4 (Suppl 1):21 Abstract not available at this time. |
| 27 | Antiviral Therapy 1999;4 (Suppl 1):22 Abstract not available at this time. |
| 28 | Antiviral Therapy 1999;4 (Suppl 1):22 Abstract not available at this time. |
| 29 | Antiviral Therapy 1999;4 (Suppl 1):23 Abstract not available at this time. |
| 30 | Antiviral Therapy 1999;4 (Suppl 1):23 Abstract not available at this time. |
| 31 | Antiviral Therapy 1999;4 (Suppl 1):25 Abstract not available at this time. |
| 32 | Antiviral Therapy 1999;4 (Suppl 1):25 Abstract not available at this time. |
| 33 | Antiviral Therapy 1999;4 (Suppl 1):26 Abstract not available at this time. |
| 34 | Antiviral Therapy 1999;4 (Suppl 1):27 Abstract not available at this time. |
| 35 | Antiviral Therapy 1999;4 (Suppl 1):27 Abstract not available at this time. |
| 36 | Antiviral Therapy 1999;4 (Suppl 1):28 Abstract not available at this time. |
| 37 | Antiviral Therapy 1999;4 (Suppl 1):29 Abstract not available at this time. |
| 38 | Antiviral Therapy 1999;4 (Suppl 1):29 Abstract not available at this time. |
| 39 | Antiviral Therapy 1999;4 (Suppl 1):30 Abstract not available at this time. |
| 40 | Antiviral Therapy 1999;4 (Suppl 1):31 Abstract not available at this time. |
| 41 | Antiviral Therapy 1999;4 (Suppl 1):31 Abstract not available at this time. |
| 42 | Antiviral Therapy 1999;4 (Suppl 1):32 Abstract not available at this time. |
| 43 | Antiviral Therapy 1999;4 (Suppl 1):33 Abstract not available at this time. |
| 44 | Antiviral Therapy 1999;4 (Suppl 1):33 Abstract not available at this time. |
| 45 | Antiviral Therapy 1999;4 (Suppl 1):34 Abstract not available at this time. |
| 46 | Antiviral Therapy 1999;4 (Suppl 1):35 Abstract not available at this time. |
| 47 | Antiviral Therapy 1999;4 (Suppl 1):35 Abstract not available at this time. |
| 48 | Antiviral Therapy 1999;4 (Suppl 1):36 Abstract not available at this time. |
| 49 | Antiviral Therapy 1999;4 (Suppl 1):37 Abstract not available at this time. |
| 50 | Antiviral Therapy 1999;4 (Suppl 1):37 Abstract not available at this time. |
| 51 | Antiviral Therapy 1999;4 (Suppl 1):38 Abstract not available at this time. |
| 52 | Antiviral Therapy 1999;4 (Suppl 1):38 Abstract not available at this time. |
| 53 | Antiviral Therapy 1999;4 (Suppl 1):39 Abstract not available at this time. |
| 54 | Antiviral Therapy 1999;4 (Suppl 1):40 Abstract not available at this time. |
| 55 | Antiviral Therapy 1999;4 (Suppl 1):41 Abstract not available at this time. |
| 56 | Antiviral Therapy 1999;4 (Suppl 1):42 Abstract not available at this time. |
| 57 | Antiviral Therapy 1999;4 (Suppl 1):42 Abstract not available at this time. |
|
Session 3: Relationship between phenotype, genotype, and clinical response Abstracts 58 thru 107, Pages 39 to 72 |
|
| 58 | Antiviral Therapy 1999;4 (Suppl 1):44 Abstract not available at this time. |
| 59 | Antiviral Therapy 1999;4 (Suppl 1):44 Abstract not available at this time. |
| 60 | Antiviral Therapy 1999;4 (Suppl 1):45 Abstract not available at this time. |
| 61 | Antiviral Therapy 1999;4 (Suppl 1):45 Abstract not available at this time. |
| 62 | Antiviral Therapy 1999;4 (Suppl 1):49 Abstract not available at this time. |
| 63 | Antiviral Therapy 1999;4 (Suppl 1):49 Abstract not available at this time. |
| 64 | Antiviral Therapy 1999;4 (Suppl 1):50 Abstract not available at this time. |
| 65 | Antiviral Therapy 1999;4 (Suppl 1):50 Abstract not available at this time. |
| 66 | Antiviral Therapy 1999;4 (Suppl 1):51 Abstract not available at this time. |
| 67 | Antiviral Therapy 1999;4 (Suppl 1):52 Abstract not available at this time. |
| 68 | Antiviral Therapy 1999;4 (Suppl 1):53 Abstract not available at this time. |
| 69 | Antiviral Therapy 1999;4 (Suppl 1):54 Abstract not available at this time. |
| 70 | Antiviral Therapy 1999;4 (Suppl 1):55 Abstract not available at this time. |
| 71 | Antiviral Therapy 1999;4 (Suppl 1):55 Abstract not available at this time. |
| 72 | Antiviral Therapy 1999;4 (Suppl 1):56 Abstract not available at this time. |
| 73 | Antiviral Therapy 1999;4 (Suppl 1):56 Abstract not available at this time. |
| 74 | Antiviral Therapy 1999;4 (Suppl 1):57 Abstract not available at this time. |
| 75 | Antiviral Therapy 1999;4 (Suppl 1):58 Abstract not available at this time. |
| 76 | Antiviral Therapy 1999;4 (Suppl 1):59 Abstract not available at this time. |
| 77 | Antiviral Therapy 1999;4 (Suppl 1):59 Abstract not available at this time. |
| 78 | Antiviral Therapy 1999;4 (Suppl 1):60 Abstract not available at this time. |
| 79 | Antiviral Therapy 1999;4 (Suppl 1):61 Abstract not available at this time. |
| 80 | Antiviral Therapy 1999;4 (Suppl 1):61 Abstract not available at this time. |
| 81 | Antiviral Therapy 1999;4 (Suppl 1):62 Abstract not available at this time. |
| 82 | Antiviral Therapy 1999;4 (Suppl 1):62 Abstract not available at this time. |
| 83 | Antiviral Therapy 1999;4 (Suppl 1):63 Abstract not available at this time. |
| 84 | Antiviral Therapy 1999;4 (Suppl 1):67 Abstract not available at this time. |
| 85 | Antiviral Therapy 1999;4 (Suppl 1):67 Abstract not available at this time. |
| 86 | Antiviral Therapy 1999;4 (Suppl 1):68 Abstract not available at this time. |
| 87 | Antiviral Therapy 1999;4 (Suppl 1):69 Abstract not available at this time. |
| 88 | Antiviral Therapy 1999;4 (Suppl 1):70 Abstract not available at this time. |
| 89 | Antiviral Therapy 1999;4 (Suppl 1):70 Abstract not available at this time. |
| 90 | Antiviral Therapy 1999;4 (Suppl 1):71 Abstract not available at this time. |
| 91 | Antiviral Therapy 1999;4 (Suppl 1):72 Abstract not available at this time. |
| 92 | Antiviral Therapy 1999;4 (Suppl 1):73 Abstract not available at this time. |
| 93 | Antiviral Therapy 1999;4 (Suppl 1):73 Abstract not available at this time. |
| 94 | Antiviral Therapy 1999;4 (Suppl 1):74 Abstract not available at this time. |
| 95 | Antiviral Therapy 1999;4 (Suppl 1):75 . |
| 96 | Antiviral Therapy 1999;4 (Suppl 1):76 Abstract not available at this time. |
| 97 | Antiviral Therapy 1999;4 (Suppl 1):76 Abstract not available at this time. |
| 98 | Antiviral Therapy 1999;4 (Suppl 1):77 Abstract not available at this time. |
| 99 | Antiviral Therapy 1999;4 (Suppl 1):78 Abstract not available at this time. |
| 100 | Antiviral Therapy 1999;4 (Suppl 1):78 Abstract not available at this time. |
| 101 | Antiviral Therapy 1999;4 (Suppl 1):79 Abstract not available at this time. |
| 102 | Antiviral Therapy 1999;4 (Suppl 1):80 Abstract not available at this time. |
| 103 | Antiviral Therapy 1999;4 (Suppl 1):80 Abstract not available at this time. |
| 104 | Antiviral Therapy 1999;4 (Suppl 1):81 Abstract not available at this time. |
| 105 | Antiviral Therapy 1999;4 (Suppl 1):82 Abstract not available at this time. |
| 106 | Antiviral Therapy 1999;4 (Suppl 1):83 Abstract not available at this time. |
| 107 | Antiviral Therapy 1999;4 (Suppl 1):83 Abstract not available at this time. |
|
Session 4: Combination therapy and transmission Abstracts 108 thru 118, Pages 73 to 82 |
|
| 108 | Antiviral Therapy 1999;4 (Suppl 1):84 Abstract not available at this time. |
| 109 | Antiviral Therapy 1999;4 (Suppl 1):85 Abstract not available at this time. |
| 110 | Antiviral Therapy 1999;4 (Suppl 1):85 Abstract not available at this time. |
| 111 | Antiviral Therapy 1999;4 (Suppl 1):89 Abstract not available at this time. |
| 112 | Antiviral Therapy 1999;4 (Suppl 1):89 Abstract not available at this time. |
| 113 | Antiviral Therapy 1999;4 (Suppl 1):90 Abstract not available at this time. |
| 114 | Antiviral Therapy 1999;4 (Suppl 1):91 Abstract not available at this time. |
| 115 | Antiviral Therapy 1999;4 (Suppl 1):92 Abstract not available at this time. |
| 116 | Antiviral Therapy 1999;4 (Suppl 1):92 Abstract not available at this time. |
| 117 | Antiviral Therapy 1999;4 (Suppl 1):93 Abstract not available at this time. |
| 118 | Antiviral Therapy 1999;4 (Suppl 1):94 Abstract not available at this time. |
|
Session 5A: Prevalence and transmission of drug resistance HIV Abstracts 119 thru 125, Pages 82 to 83 |
|
| 119 | Antiviral Therapy 1999;4 (Suppl 1):94 Abstract not available at this time. |
| 120 | Antiviral Therapy 1999;4 (Suppl 1):95 C Piketty1, A Trylesinski2, A Hill3, G Peytavin4, E Race4, A Si-Mohamed1, F Clavel4 and MD Kazatchkine1 Abstract not available at this time. |
| 121 | Antiviral Therapy 1999;4 (Suppl 1):96 Abstract not available at this time. |
| 122 | Antiviral Therapy 1999;4 (Suppl 1):97 Abstract not available at this time. |
| 123 | Antiviral Therapy 1999;4 (Suppl 1):98 Abstract not available at this time. |
| 124 | Antiviral Therapy 1999;4 (Suppl 1):98 Abstract not available at this time. |
| 125 | Antiviral Therapy 1999;4 (Suppl 1):99 Abstract not available at this time. |
|
Session 5: Pathogenesis and dynamics Abstracts 126 thru 149, Pages 83 to 104 |
|
| 126 | Antiviral Therapy 1999;4 (Suppl 1):100 Abstract not available at this time. |
| 127 | Antiviral Therapy 1999;4 (Suppl 1):100 Abstract not available at this time. |
| 128 | Antiviral Therapy 1999;4 (Suppl 1):101 Abstract not available at this time. |
| 129 | Antiviral Therapy 1999;4 (Suppl 1):102 Abstract not available at this time. |
| 130 | Antiviral Therapy 1999;4 (Suppl 1):102 Abstract not available at this time. |
| 131 | Antiviral Therapy 1999;4 (Suppl 1):103 Abstract not available at this time. |
| 132 | Antiviral Therapy 1999;4 (Suppl 1):103 Abstract not available at this time. |
| 133 | Antiviral Therapy 1999;4 (Suppl 1):104 Abstract not available at this time. |
| 134 | Antiviral Therapy 1999;4 (Suppl 1):105 Abstract not available at this time. |
| 135 | Antiviral Therapy 1999;4 (Suppl 1):105 Abstract not available at this time. |
| 136 | Antiviral Therapy 1999;4 (Suppl 1):106 Abstract not available at this time. |
| 137 | Antiviral Therapy 1999;4 (Suppl 1):107 Abstract not available at this time. |
| 138 | Antiviral Therapy 1999;4 (Suppl 1):107 Abstract not available at this time. |
| 139 | Antiviral Therapy 1999;4 (Suppl 1):108 Abstract not available at this time. |
| 140 | Antiviral Therapy 1999;4 (Suppl 1):109 Abstract not available at this time. |
| 141 | Antiviral Therapy 1999;4 (Suppl 1):110 Abstract not available at this time. |
| 142 | Antiviral Therapy 1999;4 (Suppl 1):110 Abstract not available at this time. |
| 143 | Antiviral Therapy 1999;4 (Suppl 1):111 Abstract not available at this time. |
| 144 | Antiviral Therapy 1999;4 (Suppl 1):112 Abstract not available at this time. |
| 145 | Antiviral Therapy 1999;4 (Suppl 1):112 Abstract not available at this time. |
| 146 | Antiviral Therapy 1999;4 (Suppl 1):113 Abstract not available at this time. |
| 147 | Antiviral Therapy 1999;4 (Suppl 1):114 Abstract not available at this time. |
| 148 | Antiviral Therapy 1999;4 (Suppl 1):114 Abstract not available at this time. |
| 149 | Antiviral Therapy 1999;4 (Suppl 1):115 Abstract not available at this time. |
|
Session 6: Immune reconstitution Abstracts 150 thru 160, Pages 105 to 114 |
|
| 150 | Antiviral Therapy 1999;4 (Suppl 1):116 Abstract not available at this time. |
| 151 | Antiviral Therapy 1999;4 (Suppl 1):116 Abstract not available at this time. |
| 152 | Antiviral Therapy 1999;4 (Suppl 1):117 Abstract not available at this time. |
| 153 | Antiviral Therapy 1999;4 (Suppl 1):118 Abstract not available at this time. |
| 154a | Antiviral Therapy 1999;4 (Suppl 1):119 Abstract not available at this time. |
| 154b | Antiviral Therapy 1999;4 (Suppl 1):119 Abstract not available at this time. |
| 154c | Antiviral Therapy 1999;4 (Suppl 1):120 Abstract not available at this time. |
| 155 | Antiviral Therapy 1999;4 (Suppl 1):123 Abstract not available at this time. |
| 156 | Antiviral Therapy 1999;4 (Suppl 1):123 Abstract not available at this time. |
| 157 | Antiviral Therapy 1999;4 (Suppl 1):124 Abstract not available at this time. |
| 158 | Antiviral Therapy 1999;4 (Suppl 1):125 Abstract not available at this time. |
| 159 | Antiviral Therapy 1999;4 (Suppl 1):125 Abstract not available at this time. |
| 160 | Antiviral Therapy 1999;4 (Suppl 1):126 Abstract not available at this time. |
|
Session 7: Long-term suppression/eradication Abstracts 161 thru 173, Pages 115 to 124 |
|
| 161 | Antiviral Therapy 1999;4 (Suppl 1):127 Abstract not available at this time. |
| 162 | Antiviral Therapy 1999;4 (Suppl 1):127 Abstract not available at this time. |
| 163 | Antiviral Therapy 1999;4 (Suppl 1):128 Abstract not available at this time. |
| 164 | Antiviral Therapy 1999;4 (Suppl 1):128 Abstract not available at this time. |
| 165 | Antiviral Therapy 1999;4 (Suppl 1):129 Abstract not available at this time. |
| 166 | Antiviral Therapy 1999;4 (Suppl 1):130 Abstract not available at this time. |
| 167 | Antiviral Therapy 1999;4 (Suppl 1):130 Abstract not available at this time. |
| 168 | Antiviral Therapy 1999;4 (Suppl 1):131 Abstract not available at this time. |
| 169 | Antiviral Therapy 1999;4 (Suppl 1):132 Abstract not available at this time. |
| 170 | Antiviral Therapy 1999;4 (Suppl 1):132 Abstract not available at this time. |
| 171 | Antiviral Therapy 1999;4 (Suppl 1):133 Abstract not available at this time. |
| 172 | Antiviral Therapy 1999;4 (Suppl 1):134 Abstract not available at this time. |
| 173 | Antiviral Therapy 1999;4 (Suppl 1):134 Abstract not available at this time. |
This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 1999. AEGiS.